Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

A. Belkouz; J. W. Wilmink; N. Haj Mohammad; J. Hagendoorn; J. de Vos-Geelen; C. H. C. Dejong; M. Y. V. Homs; B. Groot Koerkamp; T. M. van Gulik; M. G. H. van Oijen; C. J. A. Punt; H. Klumpen

doi:10.1016/j.critrevonc.2020.102975

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

A. Belkouz, J. W. Wilmink, N. Haj Mohammad, J. Hagendoorn, J. de Vos-Geelen, C. H. C. Dejong, M. Y. V. Homs, B. Groot Koerkamp, T. M. van Gulik, M. G. H. van Oijen, C. J. A. Punt, H. Klumpen^*

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

8 Citations (Web of Science)

Abstract

Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).

Original language	English
Article number	102975
Number of pages	9
Journal	Critical Reviews in Oncology/Hematology
Volume	151
DOIs	https://doi.org/10.1016/j.critrevonc.2020.102975
Publication status	Published - Jul 2020

Keywords

Cholangiocarcinoma
Biliary tract cancer
Adjuvant therapy
Neoadjuvant therapy
Chemotherapy
Chemoradiotherapy
PERIHILAR CHOLANGIOCARCINOMA
GEMCITABINE CHEMOTHERAPY
GALLBLADDER CARCINOMA
PROGNOSTIC-FACTORS
PLUS GEMCITABINE
RESECTION
CISPLATIN
SURVIVAL
S-1
OXALIPLATIN

Access to Document

10.1016/j.critrevonc.2020.102975

Cite this

Belkouz, A., Wilmink, J. W., Mohammad, N. H., Hagendoorn, J., de Vos-Geelen, J., Dejong, C. H. C., Homs, M. Y. V., Koerkamp, B. G., van Gulik, T. M., van Oijen, M. G. H., Punt, C. J. A., & Klumpen, H. (2020). Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. Critical Reviews in Oncology/Hematology, 151, [102975]. https://doi.org/10.1016/j.critrevonc.2020.102975

@article{43fdf78c6018442abe2767272f63fbb4,

title = "Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials",

abstract = "Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).",

keywords = "Cholangiocarcinoma, Biliary tract cancer, Adjuvant therapy, Neoadjuvant therapy, Chemotherapy, Chemoradiotherapy, PERIHILAR CHOLANGIOCARCINOMA, GEMCITABINE CHEMOTHERAPY, GALLBLADDER CARCINOMA, PROGNOSTIC-FACTORS, PLUS GEMCITABINE, RESECTION, CISPLATIN, SURVIVAL, S-1, OXALIPLATIN",

author = "A. Belkouz and Wilmink, {J. W.} and Mohammad, {N. Haj} and J. Hagendoorn and {de Vos-Geelen}, J. and Dejong, {C. H. C.} and Homs, {M. Y. V.} and Koerkamp, {B. Groot} and {van Gulik}, {T. M.} and {van Oijen}, {M. G. H.} and Punt, {C. J. A.} and H. Klumpen",

year = "2020",

month = jul,

doi = "10.1016/j.critrevonc.2020.102975",

language = "English",

volume = "151",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Science",

}

Belkouz, A, Wilmink, JW, Mohammad, NH, Hagendoorn, J, de Vos-Geelen, J , Dejong, CHC, Homs, MYV, Koerkamp, BG, van Gulik, TM, van Oijen, MGH, Punt, CJA & Klumpen, H 2020, 'Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials', Critical Reviews in Oncology/Hematology, vol. 151, 102975. https://doi.org/10.1016/j.critrevonc.2020.102975

TY - JOUR

T1 - Advances in adjuvant therapy of biliary tract cancer

T2 - an overview of current clinical evidence based on phase II and III trials

AU - Belkouz, A.

AU - Wilmink, J. W.

AU - Mohammad, N. Haj

AU - Hagendoorn, J.

AU - de Vos-Geelen, J.

AU - Dejong, C. H. C.

AU - Homs, M. Y. V.

AU - Koerkamp, B. Groot

AU - van Gulik, T. M.

AU - van Oijen, M. G. H.

AU - Punt, C. J. A.

AU - Klumpen, H.

PY - 2020/7

Y1 - 2020/7

N2 - Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).

AB - Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).

KW - Cholangiocarcinoma

KW - Biliary tract cancer

KW - Adjuvant therapy

KW - Neoadjuvant therapy

KW - Chemotherapy

KW - Chemoradiotherapy

KW - PERIHILAR CHOLANGIOCARCINOMA

KW - GEMCITABINE CHEMOTHERAPY

KW - GALLBLADDER CARCINOMA

KW - PROGNOSTIC-FACTORS

KW - PLUS GEMCITABINE

KW - RESECTION

KW - CISPLATIN

KW - SURVIVAL

KW - S-1

KW - OXALIPLATIN

U2 - 10.1016/j.critrevonc.2020.102975

DO - 10.1016/j.critrevonc.2020.102975

M3 - (Systematic) Review article

C2 - 32464483

SN - 1040-8428

VL - 151

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 102975

ER -